MRNA
Moderna, Inc (MRNA) Q4 2025 Earnings Call Transcript
Moderna, Inc (NASDAQ: MRNA) Q4 2025 Earnings Call dated Feb. 13, 2026 Corporate Participants: Lavina Talukdar — Head of Investor…
Moderna, Inc (MRNA) Sec Form 8K
Moderna, Inc (NASDAQ: MRNA) Sec Form 8K
Moderna, Inc (MRNA) Moderna Resolves Global Patent Litigation with Arbutus/Genevant
Moderna, Inc (NASDAQ: MRNA) FY 2026 Other Release
Moderna, Inc (MRNA) European Medicines Agency’s Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19
Moderna, Inc (NASDAQ: MRNA) FY 2026 Other Release
Moderna, Inc (MRNA) Sec Form 10K
Moderna, Inc (NASDAQ: MRNA) Sec Form 10K
Moderna, Inc (MRNA) Barclays 28th Annual Global Healthcare Conference
Moderna, Inc (NASDAQ: MRNA) FY 2026 Corporate Conference
Moderna, Inc (MRNA) TD Cowen 46th Annual Healthcare Conference
Moderna, Inc (NASDAQ: MRNA) FY 2026 Corporate Conference
Moderna, Inc (MRNA) Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
Moderna, Inc (NASDAQ: MRNA) FY 2026 Other Release
Moderna, Inc (MRNA) Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE
Moderna, Inc (NASDAQ: MRNA) FY 2026 Other Release
Moderna Q4 2025 net loss narrows; revenue drops 30%
Moderna, Inc. (NASDAQ: MRNA) has reported a narrower net loss for the fourth quarter of fiscal 2025, when the…